The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms
Open accessPublished version of a preprint
Abstract
Morbidity from snakebite envenoming affects approximately 400,000 people annually. Tissue damage at the bite-site often leaves victims with catastrophic life-long injuries and is largely untreatable by current antivenoms. Repurposed small molecule drugs that inhibit specific snake venom toxins show considerable promise for tackling this neglected tropical disease. Using human skin cell assays as an initial model for snakebite-induced dermonecrosis, we show that the drugs 2,3-dimercapto-1-propanesulfonic acid (DMPS), marimastat, and varespladib, alone or in combination, inhibit the cytotoxicity of a broad range of medically important snake venoms. Thereafter, using preclinical mouse models of dermonecrosis, we demonstrate that the dual therapeutic combinations of DMPS or marimastat with varespladib significantly inhibit the dermonecrotic activity of geographically distinct and medically important snake venoms, even when the drug combinations are delivered one hour after envenoming. These findings strongly support the future translation of repurposed drug combinations as broad-spectrum therapeutics for preventing morbidity caused by snakebite.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 SVMP inhibitors reduce the loss of HaCaT cell viability and/or cell death stimulated by D. russelii and B. asper venoms. HaCaT cells were treated for 24 hours with serial dilutions of D. russelii (3.125–100 µg/mL, top row) or B. asper (2.2–127 µg/mL, bottom row) venom that had been pre-incubated with drug vehicle control, DMPS (625 µM), marimastat (2.56 µM), or varespladib (256 µM). For all treatment groups, MTT cell viability (LHS of figure) and PI cell death (RHS of figure) assays were performed. * Signifies that value is significantly different than that of the vehicle control for that venom as determined by a one-way ANOVA followed by Dunnett’s multiple comparisons test (P < 0.05, n = 3 [a{M,V}, b{M, V}, d{D, V}] or 4 [a{Veh, D}, b{Veh, D}, c{Veh, D, M, V}, d{Veh, M}] biologically independent cell experiments). ANOVA statistics for individual statistically analysed graphs are: a F(3,10) = 3.969, P = 0.0422; b F(3,10) = 10.14, P = 0.0022; c F(3,12) = 29.20, P = 0.0000085; d F(3,10) = 4.677, P = 0.0273. Data are presented as mean values ± SD and the individual values for each trial are shown as points within each of the graphs. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/2ff433cdeab34e389b08f0e28fc2ca41/repurposed-drugs-and-their-combinations-prevent-morbidity-inducing-dermonecrosis-figure-3.jpg)
![Fig. 4 Varespladib potentiates the inhibitory effects of marimastat, but not DMPS, against B. asper venom in HaCaT cells. HaCaT cells were treated for 24 hours with serial dilutions of B. asper venom (2.2–190 µg/mL) that had been pre-incubated with drug vehicle control or with drug combination therapies consisting of DMPS (625 µM) plus varespladib (64 or 256 µM, abbreviated V64 or V256, respectively; top row) or marimastat (2.56 µM) plus V64 or V256 (bottom row). For all treatment groups, MTT cell viability (LHS of figure) and PI cell death (RHS of figure) assays were performed. * Signifies the value is significantly different than that of the vehicle control and ** signifies the value is significantly different than that of the marimastat-alone treatment, as determined by a one-way ANOVA comparing all treatments to each other followed by Tukey’s multiple comparisons test (P < 0.05, n = 3 [a{D & V64, D & V256}, b{D, D & V64, D & V256}, c{M & V64, M & V256}, d{M & V64, M & V256}] or 4 [a{Veh, D}, b{Veh}, c{Veh, M}, d{Veh, M}] biologically independent cell experiments). ANOVA statistics for individual statistically analysed graphs are: a F(3,10) = 26.63, P = 0.000044; b F(3,9) = 2.382, P = 0.1371; c F(3,10) = 56.55, P = 0.0000014; d F(3,10) = 40.41, P = 0.0000067. Data are presented as mean values ± SD and the individual values for each trial are shown as points within each of the graphs. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/e913eaa7c44b42daa19249901aceea8e/repurposed-drugs-and-their-combinations-prevent-morbidity-inducing-dermonecrosis-figure-4.jpg)
![Fig. 5 Dermal lesions induced by distinct snake venoms are inhibited by drug combinations containing an SVMP and a PLA2 inhibitor. Individual mice were ID injected with B. asper (150 µg), C. atrox (100 µg), or E. ocellatus (39 µg) venom or venom vehicle control (PBS) that had been pre-incubated with drug vehicle control (98.48% PBS, 1.52% DMSO; Veh), DMPS (110 µg; D), marimastat (60 µg; M), varespladib (19 µg; V), DMPS & varespladib (110 and 19 µg, respectively; DV), or marimastat & varespladib (60 and 19 µg, respectively; MV). After 72 hours† the mice were euthanised and their lesions excised, height and width measured with callipers, and photographed. a Representative images of the lesions resulting from each treatment group (black scale bar represents 3 mm). Bar graphs summarising the average total lesion areas for each drug treatment group when pre-incubated with b venom vehicle control (PBS), c B. asper, d C. atrox, or (e) E. ocellatus venom. † Signifies that these mice were culled at 24 h instead of the usual 72 h, due to their external lesions progressing to the maximum permitted size defined in our animal ethics licence, thus resulting in early euthanasia. * Signifies that value is significantly different than that of the drug vehicle control for that venom as determined by a one-way ANOVA followed by Dunnett’s multiple comparisons test (P < 0.05, n = 4 [c{M}, d{Veh}] or 5 [b{all}, c{Veh, D, V, DV, MV}, d{D, M, V, DV, MV}, e{all}] biologically independent animals). ANOVA statistics for individual statistically analysed graphs are: b F(5,24) = 1.000, P = 0.4389, c F(5,23) = 8.808, P = 0.000088; d F(5,23) = 28.80, P = 0.0000000035; e F(5,24) = 6.587, P = 0.0005. Data are presented as mean values ± SD and the individual values for each lesion are shown as points within each of the bars. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/d9ef6f8bbfb54fd38e0a3443707abcb3/repurposed-drugs-and-their-combinations-prevent-morbidity-inducing-dermonecrosis-figure-5.jpg)
![Fig. 6 Histopathological analysis of ID-injection site cross-sections confirms venom-induced dermonecrosis can be reduced using SVMP- and PLA2-inhibiting drugs. Four µm H&E sections were prepared from formalin-fixed, paraffin-embedded tissue from dermal injection sites and photographed at 100X magnification. Two blinded and independent experimenters scored, between 0–4, the percentage of each skin layer that was necrotic (0 = 0%, 1 = 0–25%, 2 = 25–50%, 3 = 50–75%, and 4 = 75–100%). The highest recorded score per cross-section was used as a measure of the maximum severity reached within each skin sample. Representative 100X-magnified images showing a no dermonecrosis (mean overall dermonecrosis score of 0), b partial dermonecrosis (1.4) and c heavy dermonecrosis (2.4), with epidermis (ED), dermis (D), hypodermis (HD), panniculus carnosus (PC), and adventitia (A) annotated in each image (note that the ED is not visible in the ‘Heavy dermonecrosis’ image due to the severity of the ulceration, and was therefore given a necrosis score of 4). Bar graphs summarising the mean overall dermonecrosis severity scores in cross-sections from mice ID-injected with d venom vehicle control (PBS), e B. asper venom, f C. atrox venom, or g E. ocellatus venom that had been pre-incubated with drug vehicle control (98.48% PBS, 1.52% DMSO; Veh), DMPS (110 µg; D), marimastat (60 µg; M), varespladib (19 µg; V), DMPS-plus-varespladib (110 and 19 µg, respectively; DV), or marimastat-plus-varespladib (60 and 19 µg, respectively; MV). † Signifies these mice were culled at 24 h instead of the usual 72 h, due to their external lesions progressing to the maximum permitted size defined in the animal ethics licence, resulting in early euthanasia. * Signifies that value is significantly different than that of the drug vehicle control as determined by a one-way ANOVA followed by Dunnett’s multiple comparisons test (P < 0.05, n = 4 [e{M}, f{Veh}] or 5 [d{all}, e{Veh, D, V, DV, MV}, f{D, M, V, DV, MV}, g{all}] biologically independent animals). ANOVA statistics: e F(5,23) = 11.81, P = 0.0000097; f F(5, 23) = 10.30, P = 0.000028; g F(5,24)1.531, P = 0.2178. Data are presented as mean values ± SD and individual scores are shown as points within each of the figures’ bars. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/44585af11b3e4f41869718ff57ffea22/repurposed-drugs-and-their-combinations-prevent-morbidity-inducing-dermonecrosis-figure-6.jpg)
![Fig. 7 The drug combination of marimastat and varespladib significantly inhibits the size of dermal lesions induced by B. asper and E. ocellatus venoms when delivered up to 1 hour after venom challenge. Mice (n = 5) were ID injected with B. asper (150 µg) or E. ocellatus (39 µg) venom and then ID injected in the same location at 0 minutes (i.e. a second injection immediately) post-venom challenge with drug vehicle control (98.48% PBS, 1.52% DMSO; Veh) or at 0-, 5-, 15-, or 60-minutes post-venom challenge with marimastat and varespladib (60 and 19 µg, respectively; MV). After 72 hours experimental animals were euthanised and their lesions excised, quantified, and photographed. a Representative images of the lesions resulting from each treatment group (black scale bar represents 3 mm). Bar graphs summarising the ability of MV to inhibit skin lesion formation caused by b B. asper and c E. ocellatus venoms at 0-, 5-, 15-, and 60-minutes post-venom challenge. * Signifies that value is significantly different than that of the drug vehicle control for that venom as determined by a one-way ANOVA followed by Dunnett’s multiple comparisons test (P < 0.05, n = 5 [all drug treatments] or 10 [vehicle controls] biologically independent animals). ANOVA statistics for individual statistically analysed graphs are: b F(4,25) = 14.27, P = 0.0000034, c F(4,25) = 12.88, P = 0.00000795. Data are presented as mean values ± SD and the individual values for each lesion are shown as points within each of the bars. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/7ba655b879d34068bc8fe89c3c6369a8/repurposed-drugs-and-their-combinations-prevent-morbidity-inducing-dermonecrosis-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Current antivenom therapy is effective only in neutralizing venom toxins in the systemic circulation and hence is ineffective in preventing local tissue injury, thus highlighting a critical gap in snakebite management and the need to develop adjunct therapeutic strategies targeting the cytotoxic mechanisms of snake venom toxins [7].”
From Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities (2026) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Kasturiratne, A., Wickremasinghe, A. R., de Silva, N., Gunawardena, N. K., Pathmeswaran, A., Premaratna, R., Savioli, L., Lalloo, D. G., & de Silva, H. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050218 · Cited by 1,935
Alkilani, A., McCrudden, M. T., & Donnelly, R. (2015) · Pharmaceutics · doi:10.3390/pharmaceutics7040438 · Cited by 1,147
Development of simple standard assay procedures for the characterization of snake venom.
Theakston, R. D. G., & REID, H. A. (1983) · Europe PMC (PubMed Central) · Cited by 674
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Winer, A., Adams, S., & Mignatti, P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0646 · Cited by 651
A Review and Database of Snake Venom Proteomes
Tasoulis, T., & Isbister, G. (2017) · Toxins · doi:10.3390/toxins9090290 · Cited by 616
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Williams, D. J., Faiz, M. A., Abela-Ridder, B., Ainsworth, S., Bulfone, T. C., Nickerson, A. D., Habib, A. G., Junghanss, T., Fan, H. W., Turner, M., et al. (2019) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007059 · Cited by 447
The Global Snake Bite Initiative: an antidote for snake bite
Williams, D., Gutiérrez, J. M., Harrison, R., Warrell, D. A., White, J., Winkel, K. D., & Gopalakrishnakone, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61159-4 · Cited by 397
Self-citationCauses and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396 · cited 2×
“…have conceptually remained unchanged for over a century and are associated with a multitude of issues including high cost, requirement for a consistent cold-chain, limited cross-snake speciesef fi cacyduetovenom variation,and high frequency of adverse events post-administration 1,8,9,17 – 20 .”
Self-citation
Research works printed but not linked: 2
- Gutiérrez, J. M. et al. Snakebite envenoming. Nat Rev Dis Primers 3, 1–21 (2017).
- Chitolie, M. S. & Toescu, E. C. High-throughput method for dynamic measurements of cellular viability using a FLUOstar OPTIMA. BMG LABTECH vol. 04 1–2 https://www.bmglabtech.com/high-throughput-method-for-dynamic-measurements-of-cellular-viability-using-a-bmg-labtech-microplate-reader/ (2008).
Cited by
Bittenbinder, M. A., van Thiel, J., Cardoso, F. C., Casewell, N. R., Gutiérrez, J.-M., Kool, J., & Vonk, F. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06019-6 · Cited by 132
Self-citationProgress and Challenges in the Field of Snakebite Envenoming Therapeutics
Gutiérrez, J. M., Casewell, N. R., & Laustsen, A. H. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022024-033544 · Cited by 48
Self-citationClare, R. H., Dawson, C. A., Westhorpe, A., Albulescu, L.-O., Woodley, C. M., Mosallam, N., Chong, D. J. W., Kool, J., Berry, N. G., O’Neill, P. M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328950 · Cited by 43
Self-citationBartlett, K. E., Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Albulescu, L.-O., Laprade, W. M., Harrison, R. A., Saviola, A. J., Modahl, C. M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315597121 · Cited by 44
Self-citationTowards better antivenoms: navigating the road to new types of snakebite envenoming therapies
Thumtecho, S., Burlet, N. J., Ljungars, A., & Laustsen, A. H. (2023) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1590/1678-9199-jvatitd-2023-0057 · Cited by 41
Metadata
- Authors
- Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R.
- Affiliations
- Liverpool School of Tropical Medicine (GB)
- Dalhousie University (CA)
- Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Casewell, Nicholas R.
- ORCID
- Venue
- Nature Communications
- Published
- 2023-12-14
- Volume
- 14
- Issue
- 1
- Pages
- 7812-7812
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10721902
- OpenAlex
- W4389736151
- Cited by
- 63
- References
- 94
- Citations by year
- 2026: 23 · 2025: 17 · 2024: 19 · 2023: 4
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Investigative News in Education (Universidad de Costa Rica) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Royal Society (NIF\R1\192161)
- Wellcome Trust (200517/Z/16/Z, 221712/Z/20/Z)
- RCUK | Medical Research Council (MR/S00016X/1)
- RCUK | MRC | Medical Research Foundation (MC_PC_15040)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Venomous Animal Envenomation and Studies
- Health Sciences › Medicine › Pharmacology (medical) › Healthcare and Venom Research
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Amphibian and Reptile Biology
- Keywords
- snakebite, dermonecrosis, repurposed drugs, combination therapy, DMPS, marimastat, varespladib, snake venom toxins, cytotoxicity inhibition, antivenom alternatives, neglected tropical diseases
- MeSH terms
- Acetates, Animals, Drug Combinations, Humans, Hydroxamic Acids, Indoles, Keto Acids, Snake Bites, Snake Venoms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms. https://app.cochat.ai/papers/10.1038/s41467-023-43510-w
- The paper
- Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023). Repurposed drugs and their combinations prevent morbidity-inducing dermonecrosis caused by diverse cytotoxic snake venoms. Nature Communications. https://doi.org/10.1038/s41467-023-43510-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.